F1‐02‐02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION

Given that Alzheimer's disease (AD) pathology precedes symptom onset, a biomarker discovery study design based on pathology rather than clinical syndromes creates the opportunity for detection of much earlier markers of disease. We have previously used such a ‘pathology endophenotype’ approach to discover plasma proteomic correlates of amyloid PET, cerebrospinal fluid (CSF) levels of amyloid-β (Aβ) and tau, brain atrophy and progression from...